Zemprocitinib, a next-generation JAK1 inhibitor, may tame rheumatoid arthritis that does not respond to at least one biologic disease-modifying antirheumatic drug, a phase 3 clinical trial finds.

Investigators assessed parsaclisib for efficacy and safety in patients with myelofibrosis and suboptimal or declining response to stable ruxolitinib.

NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion ...

Key Points Interested in Aclaris Therapeutics, Inc.? Here are five stocks we like better. Aclaris Therapeutics is preparing a ...

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

An intravitreal insert provides durable control of multiple retinal diseases, according to a presentation at Retina World ...

Operating expenses for the first quarter ended March 31, 2026, totaled $87.9 million versus $73.3 million in the prior year period. This increase was primarily attributable to ongoing DURAVYU Phase 3 ...

Livedoid vasculopathy was diagnosed. After treatment with tofacitinib combined with topical Hirudoid and Jinyin Peptide, the lesions healed. Livedoid vasculopathy (LV) is a rare, recurrent, and ...

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its ...

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence ...